Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1-20 of 1,743 trials

Acute Heart Failure: Treatment Comparison Study

We are testing different emergency treatments for pulmonary congestion in patients with acute heart failure. The goal is to see which method helps patients feel better faster after they arrive at the hospital.

Acute Heart Failure with Pulmonary Congestion>2 yearsMonitoring phase (IV)Investigational MedicinesPartially RemoteCardiologyInternal Medicine

Alzheimer's Disease and Down Syndrome: ACI-24.060 Study

We are testing a new treatment, ACI-24.060, to see if it is safe and can help generate an immune response in people with early Alzheimer's and adults with Down syndrome. This study will also look at its effects on brain amyloid levels.

Alzheimer's Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Cholangiocarcinoma: Comparing RFA and PDT Treatments

We are studying whether radiofrequency ablation or photodynamic therapy helps patients with cholangiocarcinoma live longer. We’ll also look at how these treatments affect quality of life and any potential side effects.

Hilar Cholangiocarcinoma>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyOncology

Heart Attack Treatment: The Dan-DAPT Trial

We are testing a tailored blood-thinning strategy for heart attack patients at high bleeding risk. The goal is to see if this approach can lower bleeding without raising the chance of heart problems.

Heart Attack>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesPartially RemoteCardiologyInternal Medicine

Cardiac AL Amyloidosis: [18F]florbetaben PET Imaging Study

We are evaluating a new imaging technique to improve the diagnosis of cardiac AL amyloidosis in patients. This study will help us understand how well it works compared to current diagnostic methods.

Cardiac AmyloidosisAL AmyloidosisATTR Amyloidosis>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Alpelisib for Megalencephaly-Capillary Malformation Polymicrogyria Syndrome (MCAP)

We are studying whether alpelisib can improve adaptive behavior and overall health in children and adults with MCAP. The trial will also assess the safety and effects of the treatment on brain and spinal cord health.

PIK3CA Related Overgrowth SpectrumMegalencephaly-Capillary Malformation-Polymicrogyria Syndrome>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesInternal MedicineNeurologyPediatrics

Hydrochlorothiazide for Polycystic Kidney Disease Patients

We are studying whether adding hydrochlorothiazide to tolvaptan can help slow kidney function decline in people with polycystic kidney disease. This trial also looks at how this combination affects quality of life and treatment tolerability.

Autosomal Dominant Polycystic Kidney Disease>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteInternal MedicineNephrology

Kidney Transplant: Imlifidase for Highly Sensitized Children

We are studying whether imlifidase can help children with high sensitization receive a kidney transplant by improving compatibility with the donor. This trial will also look at kidney function and overall safety of the treatment.

Kidney Transplant Rejection>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

Advanced Breast Cancer: RLY-2608 Treatment Study

We are testing a new treatment called RLY-2608 for individuals with advanced breast cancer and other solid tumors. This study aims to understand how safe and effective this treatment may be.

Advanced Solid Tumor with PIK3CA Mutation>2 yearsSafety phase (I)Oncology

Parkinson's Disease: ACI-7104.056 Vaccine Study

We are testing a new vaccine to see if it is safe and can help improve symptoms in people with early-stage Parkinson's disease. The study will also look at how the vaccine affects certain biological markers related to the disease.

Early Stages of Parkinson's Disease>2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Preventing Bronchopulmonary Dysplasia: New Treatment for Preterm Newborns

We are studying a new therapy using cell-derived vesicles to see if it can help prevent lung problems in extremely preterm newborns. This trial will assess both safety and effectiveness compared to a placebo.

Bronchopulmonary Dysplasia>2 yearsSafety phase (I)Efficacy phase (II)Investigational MedicinesPediatricsPulmonology

Acute Myeloid Leukemia: CPX-351 vs. Standard Chemotherapy

We are studying whether a new treatment called CPX-351 can help patients with specific types of acute myeloid leukemia achieve better remission compared to standard chemotherapy. This trial focuses on patients with de novo intermediate or adverse risk AML.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Chronic Lymphocytic Leukemia: Venetoclax and Epcoritamab Study

We are studying a combination of venetoclax and epcoritamab in patients with relapsed or refractory CLL or SLL. The goal is to see if this treatment improves disease control and overall survival compared to existing options.

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Heart Attack Recovery: Dabigatran vs. Vitamin K Antagonist

We are studying whether the medication Dabigatran helps patients with blood clots in the heart after a heart attack recover better than a traditional treatment. This trial looks at how well each treatment resolves the clot and prevents complications.

STEMI (ST Elevation Myocardial Infarction)Left Ventricular Thrombosis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Febrile Neutropenia: SAFE Study on Short Antibiotic Treatment

We are studying whether stopping antibiotics after 3 days is as safe as continuing them longer for patients with febrile neutropenia. This research aims to find a potentially safer treatment approach for hematology patients.

Febrile Neutropenia>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesHematologyInfectious Diseases

Peripheral T-Cell Lymphoma: Tolinapant with Decitabine/Cedazuridine

We are studying a new treatment combining tolinapant with oral decitabine/cedazuridine for patients with relapsed or refractory peripheral T-cell lymphoma. The goal is to assess safety and effectiveness compared to the current standard treatment.

T-cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Risankizumab for Moderate to Severe Plaque Psoriasis in Children and Teens

We are studying the long-term safety and effectiveness of risankizumab in children and teens aged 6 to 17 with moderate to severe plaque psoriasis. This follows their participation in a previous study to see how well the treatment works over time.

Plaque Psoriasis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesAllergologyDermatology

Cardiac Surgery: Vasopressin vs. Norepinephrine

We are comparing two medications to see which better protects kidney function and reduces complications in patients at risk during cardiac surgery. This study aims to improve outcomes for those undergoing surgery with heart-lung machines.

Vasoplegic Syndrome>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCardiologyInternal MedicineNephrologyOtolaryngology

Anemia in Low-Risk Myelodysplastic Syndrome: Luspatercept vs Epoetin Alfa

We are comparing a new treatment, luspatercept, with a standard treatment, epoetin alfa, for patients with low-risk myelodysplastic syndrome who do not need blood transfusions. The goal is to see which treatment better helps manage anemia.

Myelodysplastic Syndrome (MDS)>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyInternal Medicine

Preventing Dementia: Metformin and Lifestyle Changes

We are studying whether a combination of metformin and a structured lifestyle program can help older adults at risk for dementia improve their cognitive abilities and overall health compared to a self-guided approach.

Cognitive Impairment Prevention>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteGastroenterologyNeurology